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DAdditional input from studies on other transcatheter
heart valves may answer questions on whether the
percutaneous approach is a possible risk factor along
with other substrates based on prosthetic material.
Despite a higher incidence of endocarditis with the
Melody valve, probabilities of survival and event-free
survival were similar to the surgical group.
The authors thank Dr Mehul Patel for editing the paper.
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Dis. 2012;105:454-60.MMENTARYEndocarditis and the transcatheter pulmonary valveRichard A. Jonas, MDThe article in this issue of the Journal by Malekzadeh-
Milani and colleagues1 from the pediatric cardiology
department at the renowned Necker Hospital in Paris re-
ports a disturbingly high risk for endocarditis in the Melody
valve (Medtronic Inc, Minneapolis, Minn) relative to surgi-
cally implanted conduits. Surgically implanted conduits
containing a bovine jugular valve (Contegra conduits; Med-
tronic Inc) also appear to have a higher risk of endocarditis
relative to other surgical options.
This is an important article. There have been an
increasing number of anecdotal reports in the literature sug-
gesting that the Melody valve might have a higher risk for
endocarditis than surgically implanted pulmonary valves.
A multi-institutional report in 2013 described an importantdiovascular Surgery c Volume 148, Number 5 2259
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Dincidence of endocarditis in 3 ongoing prospective trials of
the Melody valve.2 A recent abstract presented at the Pedi-
atric and Adult Interventional Cardiac Symposium in Chi-
cago also has come to the conclusion that the Melody
valve may be uniquely susceptible to endocarditis.3 The
current report1 describes a relatively large and contempo-
raneous experience that examines the issue in greater
detail. The findings are certainly of concern. Melody valve
endocarditis occurred earlier (P ¼ .0065) and tended to
have a higher mortality risk relative to endocarditis in a
surgically implanted valve (37% vs 13%). There was
less likely to be a past history of endocarditis in patients
with endocarditis in a Melody valve than in patients with
endocarditis in surgically implanted valves. Some patients
presented with severe symptoms, including cardiogenic
shock and renal failure, as we have also seen recently in
Washington, DC, in a previously healthy 17-year-old pa-
tient not reported previously.
The risk of endocarditis in surgically implanted homo-
grafts and surgically implanted bioprosthetic valves has
been so low that most pediatric cardiac surgical teams are
probably unfamiliar with the ‘‘Duke criteria’’ (Table 1)
that the authors have used to define the occurrence of endo-
carditis.1 The authors also have provided suggestions for
management that will be helpful for those groups encoun-
tering this problem for the first time.1 Their management
strategy is based on European Society of Cardiology guide-
lines.4 Antimicrobial therapy was given for 6 weeks. Indica-
tions for surgery were heart failure (secondary to increased
right ventricular outflow tract obstruction), uncontrolled
sepsis with septic shock, or persisting infection in the urgent
cases. In semi-elective or elective surgery, the reason for
intervention was right ventricular outflow tract obstruction
or relapse of endocarditis despite adequate antibiotic treat-
ment. These indications for surgery are similar to those that
would be applied for native valve endocarditis and are less
aggressive than would be applied for endocarditis of a pros-
thetic aortic or mitral valve. Perhaps the lesser hemody-
namic burden on a right-sided valve justifies such an2260 The Journal of Thoracic and Cardiovascular Surapproach. Until more experience is acquired with this new
problem, great care will need to be taken if a conservative
nonoperative approach is taken.
An intriguing aspect of the report is the observation that the
Contegra bovine jugular conduit also has been observed to
have a higher risk of endocarditis than other conduits, partic-
ularly homografts. The authors have speculated, as have
others whom the authors cite, that there may be an intrinsic
susceptibility of bovine jugular tissue to infection. One won-
ders whether the ‘‘cheese-grater’’ effect of a metal stent
immediately adjacent to the bovine jugular valve in the Mel-
ody implant is responsible for the even greater incidence of
endocarditis in the Melody valve relative to the Contegra
conduit.
It is important to remember the history of surgically
implanted valves and conduits when multiple unanticipated
problems were encountered, often many years after im-
plantation, including ball valve embolization from the
Braunwald-Cutter valve (Cutter Laboratories Inc, Berkeley,
Calif) and strut fracture of the widely applied Bjork-Shiley
valve (Shiley, Inc, Irvine, Calif). The Melody valve is the
first generation of catheter-implanted valves. Unanticipated
late problems should be anticipated.
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